2022
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 322-334. PMID: 35390768, DOI: 10.6004/jnccn.2022.0021.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaNCCN guidelinesClassical HLNodular lymphocyte predominant Hodgkin lymphomaLymphocyte predominant Hodgkin lymphomaNCCN Guidelines InsightsModern treatment optionsManagement of patientsB-cell originClassical Hodgkin lymphomaLong-term toxicityUncommon malignancyCure rateTreatment optionsTreatment considerationsDose constraintsLymphomaRecent updatesGuidelinesPatientsMalignancy
2012
Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2010
A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.
Lansigan F, Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood 2010, 116: 2816. DOI: 10.1182/blood.v116.21.2816.2816.Peer-Reviewed Original ResearchDose level 3Stem cell transplantStable diseaseHL patientsHodgkin's lymphomaPartial responseRefractory lymphomaCell transplantCardiac toxicityDisease progressionLiposomal doxorubicinLymphoplasmacytic lymphomaGrade 3Prior treatmentAST/ALT elevationAutologous stem cell transplantMedian age 69 yearsAllogeneic stem cell transplantPeripheral T-cell lymphomaTherapy warrants further investigationDisease controlLarge B-cell lymphomaDose level 1Dose level 2Doses of vorinostat
1999
Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option
Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAntibiotic ProphylaxisAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLymphoma, Non-HodgkinMelphalanMiddle AgedNeutropeniaPodophyllotoxinRetrospective StudiesConceptsPeripheral blood progenitor cell transplantHigh-dose chemotherapyAbsolute neutrophil countProgenitor cell transplantCell transplantHodgkin's diseaseHodgkin's lymphomaHerpes simplex virus serologyHigh-dose BEAM chemotherapyGram-positive bacteremiaDuration of neutropeniaRisk of bacteremiaPeriod of neutropeniaMultivariate logistic regressionInvasive fungal infectionsRisk of developmentNumber of CD34Amphotericin therapyBEAM chemotherapyFebrile neutropeniaNeutropenic infectionOral ciprofloxacinWBC engraftmentProphylactic antibioticsCare visits